%0 Journal Article
%T Genomic instabilities in hepatocellular carcinoma: biomarkers and application in immunotherapies.
%A Hung JH
%A Teng CF
%A Hung HC
%A Chen YL
%A Chen PJ
%A Ho CL
%A Chuang CH
%A Huang W
%J Ann Hepatol
%V 29
%N 6
%D 2024 Aug 14
%M 39147130
%F 3.388
%R 10.1016/j.aohep.2024.101546
%X Hepatocellular carcinoma (HCC) is one of the deadliest cancers. For patients with advanced HCC, liver function decompensation often occurs, which leads to poor tolerance to chemotherapies and other aggressive treatments. Therefore, it remains critical to develop effective therapeutic strategies for HCC. Etiological factors for HCC are complex and multifaceted, including hepatitis virus infection, alcohol, drug abuse, chronic metabolic abnormalities, and others. Thus, HCC has been categorized as a "genomically unstable" cancer due to the typical manifestation of chromosome breakage and aneuploidy, and oxidative DNA damage. In recent years, immunotherapy has provided a new option for cancer treatments, and the degree of genomic instability positively correlates with immunotherapy efficacies. This article reviews the endogenous and exogenous causes that affect the genomic stability of liver cells; it also updates the current biomarkers and their detection methods for genomic instabilities and relevant applications in cancer immunotherapies. Including genomic instability biomarkers in consideration of cancer treatment options shall increase the patients' well-being.